MTSR
Metsera Inc
$
33.190
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
33.380
Open
33.135
VWAP
32.74
Vol
937.34K
Mkt Cap
--
Low
31.730
Amount
30.69M
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Metsera, Inc. is a clinical-stage biotechnology company developing injectable and oral nutrient stimulated hormone (NuSH) analog peptides to treat obesity, overweight and related conditions. The Company uses its proprietary MINT peptide library of NuSH analog peptides alongside its Half-life Augmentation by Lipid Optimization, or HALO, half-life extending platform and its MOMENTUM oral NuSH analog peptide delivery platform to deliver highly differentiated product candidates. Its product pipeline includes MET-097i, MET-233i / MET-233i + MET-097i and MET-224o. MET-097i, its advanced product candidate, is a fully biased, monthly, subcutaneously injectable ultra-long acting GLP-1 RA. MET-233i is a subcutaneously injectable ultra-long-acting amylin analog, with enhanced solubility and miscibility with its other NuSH analog peptides. MET-224o is an oral, fully biased ultra-long acting GLP-1 RA. The Company's pipeline also includes MET-002o, MET-AMYo, MET-034i, MET-067i and MET-PYYi.
Show More
3 Analyst Rating
Wall Street analysts forecast MTSR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MTSR is 57.33 USD with a low forecast of 45.00 USD and a high forecast of 65.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 33.190
Low
45.00
Averages
57.33
High
65.00
Current: 33.190
Low
45.00
Averages
57.33
High
65.00
BofA
Buy
maintain
$38 -> $45
2025-07-20
Reason
BofA
Price Target
$38 -> $45
2025-07-20
maintain
Buy
Reason
BofA raised the firm's price target on Metsera to $45 from $38 and keeps a Buy rating on the shares after the company announced the first round of clinical data on its amylin agonist, MET-233i. The firm views the data as competitive and "partially de-risking" to the program. It upped its probability of success for MET-233i to 45% from 30%.
Goldman Sachs
Corinne Johnson
initiated
2025-07-10
Reason
Goldman Sachs
Corinne Johnson
Price Target
2025-07-10
initiated
Reason
Goldman Sachs analyst Corinne Johnson started Metsera with an Early-Stage Biotech rating.
Wells Fargo
Cerena Chen
Overweight
initiated
$65
2025-06-21
Reason
Wells Fargo
Cerena Chen
Price Target
$65
2025-06-21
initiated
Overweight
Reason
Wells Fargo analyst Cerena Chen initiated coverage of Metsera with an Overweight rating and $65 price target. The company "stands out" in a "crowded" obesity landscape with assets that promise monthly dosing and competitive efficacy without tolerability tradeoffs, the analyst tells investors in a research note. Wells sees a good risk/reward at current levels, saying data over the next year will strengthen Metsera's "differentiated profile." The firm points out the company's platform so far has delivered assets with 18- and 19-day half-lives.
Guggenheim
Buy
upgrade
$56 -> $62
2025-06-10
Reason
Guggenheim
Price Target
$56 -> $62
2025-06-10
upgrade
Buy
Reason
Guggenheim raised the firm's price target on Metsera to $62 from $56 and keeps a Buy rating on the shares, telling investors that preliminary 5-week amylin data for the MET-233i monotherapy program exceeded the firm's expectations. Following the report of the data, the firm is increasing its view of MET-233i odds of success to 65% from 50%, the analyst noted.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Metsera Inc (MTSR.O) is -9.22, compared to its 5-year average forward P/E of -8.07. For a more detailed relative valuation and DCF analysis to assess Metsera Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-8.07
Current PE
-9.22
Overvalued PE
-5.28
Undervalued PE
-10.86
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-7.06
Current EV/EBITDA
-7.28
Overvalued EV/EBITDA
-4.70
Undervalued EV/EBITDA
-9.43
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
FY2025Q2
-71.12M
Operating Profit
FY2025Q2
-68.72M
Net Income after Tax
FY2025Q2
-0.66
EPS - Diluted
FY2025Q2
-59.16M
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
10
35.4M
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
MTSR News & Events
Events Timeline
2025-07-28 (ET)
2025-07-28
16:45:31
Metsera reports Q2 EPS (66c), consensus (68c)
2025-07-17 (ET)
2025-07-17
10:00:05
Metsera falls -7.6%
2025-06-09 (ET)
2025-06-09
13:31:21
Metsera obesity monotherapy data 'looks competitive,' says BofA
Sign Up For More Events
Sign Up For More Events
News
3.0
08-22NASDAQ.COMExplore the Potential: XBI Could Rise by 55%
9.0
08-20Yahoo FinanceMetsera's (MTSR) Amylin Agonist Results Prompt Price Target Raise
9.5
07-28NASDAQ.COMMetsera, Inc. Loss At -$68.72 Mln In Q2
Sign Up For More News
People Also Watch
WMT
Walmart Inc
96.050
USD
-0.02%
TSLA
Tesla Inc
351.670
USD
+1.46%
AVGO
Broadcom Inc
298.010
USD
+1.28%
META
Meta Platforms Inc
754.100
USD
+0.11%
MSFT
Microsoft Corp
502.040
USD
-0.44%
XOM
Exxon Mobil Corp
111.490
USD
-0.22%
AAPL
Apple Inc
229.310
USD
+0.95%
ORCL
Oracle Corp
234.210
USD
-0.51%
NVDA
NVIDIA Corp
181.770
USD
+1.09%
AMZN
Amazon.com Inc
228.710
USD
+0.34%
FAQ
What is Metsera Inc (MTSR) stock price today?
The current price of MTSR is 33.19 USD — it has increased 1.84 % in the last trading day.
What is Metsera Inc (MTSR)'s business?
What is the price predicton of MTSR Stock?
What is Metsera Inc (MTSR)'s revenue for the last quarter?
What is Metsera Inc (MTSR)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Metsera Inc (MTSR)'s fundamentals?
How many employees does Metsera Inc (MTSR). have?